News
10 August 2022

World Cancer Leaders’ Summit in Long Beach, CA – 16-17 October 2023

The World Cancer Leaders’ Summit is the premier event in global cancer control to help guide united and coordinated international, national and regional responses to the cancer epidemic.

Every two years, UICC brings together key decision makers in cancer control and public health from around the world at the World Cancer Leaders’ Summit. In 2023, some 300 global influencers from across governments, UN agencies, academia, non-profit organisations and the private sector will gather in Long Beach, California on 16-17 October. 

This premier event offers participants a unique opportunity to exchange perspectives on the opportunities and challenges facing the cancer community. Importantly, the high-level meetings address issues of international as well as regional and national importance, with discussions focused on tailored responses. The specific theme for next year’s edition will be announced shortly.

The event will be hosted by the American Society of Clinical Pathology, a UICC full member. The World Cancer Leaders’ Summit also partners traditionally with the World Health Organization (WHO), the International Agency for Research on Cancer (IARC) and the International Atomic Energy Agency (IAEA).

Find out more about the World Cancer Leaders' Summit

Participation in the World Cancer Leaders’ Summit is by invitation only, without registration fees. 

Last update

Monday 27 February 2023

Share this page

Related content

Event crowd at a professional conference

Participants explored practical solutions to expand access to quality cancer care, focusing on inclusive delivery models, emerging technologies, and strategies tailored to local needs and system capacity.

Ulrika Årehed Kågström, President of UICC, in orange suit against branded blue background

The World Cancer Declaration 2025-2035 introduces a “5×5×5 by 2035” framework: five global targets, five national action domains, and five core principles to guide countries in advancing equitable, evidence-based cancer control.